JP7794735B2 - 切替え療法によるrmsの治療 - Google Patents

切替え療法によるrmsの治療

Info

Publication number
JP7794735B2
JP7794735B2 JP2022515966A JP2022515966A JP7794735B2 JP 7794735 B2 JP7794735 B2 JP 7794735B2 JP 2022515966 A JP2022515966 A JP 2022515966A JP 2022515966 A JP2022515966 A JP 2022515966A JP 7794735 B2 JP7794735 B2 JP 7794735B2
Authority
JP
Japan
Prior art keywords
ofatumumab
pharmaceutical composition
disease
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022515966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548575A5 (cg-RX-API-DMAC7.html
JP2022548575A (ja
Inventor
ラマナサン,クリシュナン
エイドリアン ヘリング,ディーター
バガー,モルテン
メルシュヘムケ,マルティン
ツィーン,マリナ
ピンギリ,ラトネーカー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72709332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7794735(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022548575A publication Critical patent/JP2022548575A/ja
Publication of JP2022548575A5 publication Critical patent/JP2022548575A5/ja
Priority to JP2025159217A priority Critical patent/JP2026016387A/ja
Application granted granted Critical
Publication of JP7794735B2 publication Critical patent/JP7794735B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022515966A 2019-09-11 2020-09-10 切替え療法によるrmsの治療 Active JP7794735B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025159217A JP2026016387A (ja) 2019-09-11 2025-09-25 切替え療法によるrmsの治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19196789.2 2019-09-11
EP19196789 2019-09-11
EP20154736.1 2020-01-30
EP20154736 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025159217A Division JP2026016387A (ja) 2019-09-11 2025-09-25 切替え療法によるrmsの治療

Publications (3)

Publication Number Publication Date
JP2022548575A JP2022548575A (ja) 2022-11-21
JP2022548575A5 JP2022548575A5 (cg-RX-API-DMAC7.html) 2023-09-13
JP7794735B2 true JP7794735B2 (ja) 2026-01-06

Family

ID=72709332

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515966A Active JP7794735B2 (ja) 2019-09-11 2020-09-10 切替え療法によるrmsの治療
JP2025159217A Pending JP2026016387A (ja) 2019-09-11 2025-09-25 切替え療法によるrmsの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025159217A Pending JP2026016387A (ja) 2019-09-11 2025-09-25 切替え療法によるrmsの治療

Country Status (15)

Country Link
US (1) US20220298253A1 (cg-RX-API-DMAC7.html)
EP (2) EP3864053B1 (cg-RX-API-DMAC7.html)
JP (2) JP7794735B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062025A (cg-RX-API-DMAC7.html)
CN (3) CN118436777A (cg-RX-API-DMAC7.html)
AU (1) AU2020344154A1 (cg-RX-API-DMAC7.html)
CA (1) CA3150947A1 (cg-RX-API-DMAC7.html)
DK (1) DK3864053T3 (cg-RX-API-DMAC7.html)
ES (1) ES2957112T3 (cg-RX-API-DMAC7.html)
FI (1) FI3864053T3 (cg-RX-API-DMAC7.html)
IL (1) IL290619A (cg-RX-API-DMAC7.html)
LT (1) LT3864053T (cg-RX-API-DMAC7.html)
MX (1) MX2022003010A (cg-RX-API-DMAC7.html)
SI (1) SI3864053T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4252847A3 (en) 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2021204994A1 (en) * 2020-04-09 2021-10-14 Novartis Ag Ofatumumab for treating ms while maintaining serum igg
CA3215371A1 (en) * 2021-04-13 2022-10-20 Shibeshih Mitiku BELACHEW Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
CN117529336A (zh) * 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
EP4252847A3 (en) * 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Multiple Sclerosis Journal, 2018, Vol. 24, No. S2, pp. 526-527
Neurology, 2014, Vol. 82, pp. 573-581
Neurology, 2018, Vol. 90, pp. e1805-e1814, Short-form article, Supplementary Methods and Results
NOVARTIS, A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis,2018年08月06日, [retrieved on 2024.06.05], Retrieved from the Internet: <URL: https://cdn.clinicaltrials.gov/large-docs/31/NCT02792231/Prot_001.pdf>

Also Published As

Publication number Publication date
AU2020344154A1 (en) 2022-04-07
EP4230655A2 (en) 2023-08-23
CN114401742A (zh) 2022-04-26
CN118403156A (zh) 2024-07-30
EP3864053B1 (en) 2023-07-05
DK3864053T3 (da) 2023-09-11
JP2026016387A (ja) 2026-02-03
LT3864053T (lt) 2023-09-11
CN114401742B (zh) 2024-05-24
SI3864053T1 (sl) 2023-12-29
CN118436777A (zh) 2024-08-06
MX2022003010A (es) 2022-06-02
US20220298253A1 (en) 2022-09-22
IL290619A (en) 2022-04-01
CA3150947A1 (en) 2021-03-18
KR20220062025A (ko) 2022-05-13
EP4230655A3 (en) 2023-11-01
FI3864053T3 (fi) 2023-09-13
EP3864053A1 (en) 2021-08-18
WO2021048280A1 (en) 2021-03-18
JP2022548575A (ja) 2022-11-21
ES2957112T3 (es) 2024-01-11

Similar Documents

Publication Publication Date Title
EP3864053B1 (en) Treatment of rms by switching therapy
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
Lopalco et al. Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis
CA3229704A1 (en) Ofatumumab for treating pediatric ms
JP2026009900A (ja) 血清IgGを維持しながらMSを治療するためのオファツムマブ
US20240228647A1 (en) Ofatumumab for treating multiple sclerosis in asian patients
CN114375306A (zh) 奥法木单抗治疗患者中除多发性硬化症以外病症的管理
AU2018361975A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
RU2849464C1 (ru) Лечение rms путем смены терапии
HK40051003B (en) Treatment of rms by switching therapy
HK40051003A (en) Treatment of rms by switching therapy
WO2017120261A1 (en) Methods of treating type 2 diabetes mellitus using glucagon receptor antagonistic antibodies
Mahdavian et al. Multiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗
TW202300523A (zh) 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB)
Bašić Kes et al. Preporuke za dijagnostiku i liječenje multiple skleroze
Kerry Maximizing the Effectiveness of Pharmacotherapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251218

R150 Certificate of patent or registration of utility model

Ref document number: 7794735

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150